08.05.2026 10:30 Rita Longobardi
Meet Edwige Guinet, CEO of Visienco. The biotech company develops AI-powered lab automation and data tools for organoid research. Edwige and the other nine Swiss National Biotech Team members will travel to Boston in June.
Name: Edwige Guinet
Location: Technopark Luzern
Nationality: French
Graduated from: EDHEC Business School
Prior role: CEO & Co-Founder
Founding team members: 3
Number of employees: 4 FTE eq.
Money raised: CHF 820k
What does your product or solution do, and what makes it unique?
Visienco's first solution, the Orgadroid, automates the selection, characterization, and transfer of 3D tissues, one of the most manual steps in organoid workflows. Designed specifically for 3D biology, it handles a wide range of tissues and combines imaging, AI, and precise robotics to replace hours of manual work with a fast, reproducible process.
What trend or shift in your industry is currently creating the biggest opportunity for you?
The shift from 2D cultures to organoids and 3D models is transforming drug discovery, offering better human relevance but limited scalability due to manual workflows. Visienco addresses this gap. With regulators like the FDA and EMA pushing to reduce animal testing, the field is reaching an inflection point. Built with organoid pioneers, Orgadroid positions us to lead as the market industrializes.
How did the idea for your startup originate?
The technology originated from market demand, when Swiss organoid pioneers asked CSEM to solve the bottleneck of manual organoid sorting. This led to years of R&D with partners like the Institute of Ophthalmology Basel and a major Swiss pharma company. Through these collaborations, we saw that biology was advancing faster than workflows, this gap ultimately led to the creation of the startup.
Which market are you addressing, and what potential do you see for your startup in that market?
Our target market includes pharma, biotech, CROs, and research institutions using 3D cell models. With regulatory shifts boosting organoid adoption, the automation market could reach ~USD 4B by 2033. We also see opportunities in clinical applications and, longer term, in cosmetics and food biotech.
What impact do you want your technology to have five years from now?
In five years, we aim for widespread use of organoids in R&D and growing clinical adoption to guide personalized treatments. Standardizing workflows across labs is the first step to enable efficient research, reduce animal testing, and speed up treatment access. With ongoing clinical discussions, we see Orgadroid as key infrastructure for this shift toward personalized medicine.
What major challenges have you faced so far?
As a startup founder, I’d highlight two key challenges. First, market perception: organoids were once seen as niche, but growing regulatory support and industry interest have repositioned them as a major opportunity, accelerating our discussions with pharma and investors. Second, our non-biological background: coming from engineering and robotics was a strength, but required building strong partnerships with IOB and pharma to establish scientific credibility.
What motivates you on tough days?
Motivation comes from working closely with scientists and seeing how our solution helps them achieve their goals faster. The clinical potential, helping patients receive the right treatment sooner, adds further drive, especially through collaborations with partners like cancer hospitals. Reflecting on our team’s progress and resilience also keeps us moving forward.
Why did you decide to join the Venture Leaders Roadshow, and what are you most excited about?
Boston is currently our most important biotech ecosystem. We are already in discussions with key players, and a week on site helps accelerate what would otherwise take months remotely. The Venture Leaders Roadshow offers a strong network and a solid platform to engage with leading stakeholders. I look forward to gathering feedback and advancing ongoing discussions.
